Clinical Trials Sponsored by The Lymphoma Academic Research Organisation

Total 726 results

The Lymphoma Academic Research Organisation

Recruiting

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Marginal Zone Lymphoma

France
The Lymphoma Academic Research Organisation

Active, not recruiting

Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance (LyMa101)

Mantle Cell Lymphoma

France
The Lymphoma Academic Research Organisation

Active, not recruiting

R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL

Mantle Cell Lymphoma

France, Spain, Belgium, Netherlands, Germany, Poland, Portugal
The Lymphoma Academic Research Organisation

Active, not recruiting

Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Aggressive Non-Hodgkin Lymphoma

France, Belgium
The Lymphoma Academic Research Organisation

Completed

Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

Follicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Mucosa Associated Lymphoid Tissue

France
The Lymphoma Academic Research Organisation

Completed

Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL) (RT3)

Diffuse Large B Cell Lymphoma

France
The Lymphoma Academic Research Organisation

Terminated

BRIEF Bendamustine and Rituximab In Elderly Follicular (BRIEF)

Follicular Lymphoma

France, Belgium
The Lymphoma Academic Research Organisation

Recruiting

Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older

DLBCL

France, Belgium
The Lymphoma Academic Research Organisation

Completed

Detection and Characterization of Residual Masses in Lymphomas (ADAMANTIUS)

Hodgkin Lymphoma | B-Cell Lymphoma

France
The Lymphoma Academic Research Organisation

Completed

Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

Refractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma

France, Belgium
The Lymphoma Academic Research Organisation

Completed

Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma

Hodgkin Lymphoma | Coexisting Medical Conditions

France, Belgium
The Lymphoma Academic Research Organisation

Completed

Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma (iLOC)

Intraocular Lymphoma | Primary Central Nervous Lymphoma

France
The Lymphoma Academic Research Organisation

Completed

Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)

T-cell Lymphoma

France, Belgium
The Lymphoma Academic Research Organisation

Completed

Study of Mini-Chop Plus Ofatumumab To Treat Cd 20+ Diffuse Large B-Cell Lymphoma In Patients Aged Over 80 Years

Non Previously Treated CD20+ Diffuse Large B-cell Lymphoma

Belgium, France
The Lymphoma Academic Research Organisation

Completed

The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's Lymphomas ((RAD001-R))

Non-Hodgkin's Lymphomas

France
The Lymphoma Academic Research Organisation

Recruiting

Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry

Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL)

Belgium, France
The Lymphoma Academic Research Organisation

Active, not recruiting

Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

Refractory Indolent Adult Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma | Diffuse Large B-Cell Lymphoma Refractory | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Refractory Primary Mediastinal Large B-Cell Cell Lymphoma

France
The Lymphoma Academic Research Organisation

Completed

A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage III-IV HIV-associated Hodgkin Lymphoma (AMC-085)

HIV Infection | Stage III Adult Hodgkin Lymphoma | Stage IV Adult Hodgkin Lymphoma | HIV-associated Hodgkin Lymphoma

France
The Lymphoma Academic Research Organisation

Active, not recruiting

Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation

B-cell Lymphoma Recurrent | B-Cell Lymphoma Refractory

France, Belgium
The Lymphoma Academic Research Organisation

Completed

Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma

Follicular Lymphoma Patients (Phase IB) | Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II)

France, Belgium
The Lymphoma Academic Research Organisation

Completed

Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Peripheral T-cell Lymphoma

Spain, France, Korea, Republic of, Italy, Germany, Singapore, Belgium, Portugal
The Lymphoma Academic Research Organisation

Completed

Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD (BRAPP2)

Hodgkin Lymphoma

France
The Lymphoma Academic Research Organisation

Completed

Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP (REMARC)

Lymphoma | Diffuse Large B-cell Lymphoma

Belgium, Switzerland, France, Australia, Spain, Israel, Austria, Portugal, Poland
The Lymphoma Academic Research Organisation

Completed

Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin (PVAB)

Classical Hodgkin Lymphoma

France, Belgium
The Lymphoma Academic Research Organisation

Terminated

Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy

DLBCL

Belgium, France
The Lymphoma Academic Research Organisation

Completed

A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas (Ro-CHOP)

Peripheral T Cell Lymphoma

France
Celgene
The Lymphoma Academic Research Organisation

Active, not recruiting

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma (RELEVANCE)

Follicular Lymphoma

United States, Japan
The Lymphoma Academic Research Organisation
Celgene

Active, not recruiting

Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL

Relapsed Angioimmunoblastic T-Cell Lymphoma | Refractory Angioimmunoblastic T-cell Lymphoma

France, Denmark, United Kingdom, Austria, Belgium
The Lymphoma Academic Research Organisation
Pfizer

Completed

Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse

Diffuse Large B-Cell Lymphoma

France, Belgium
The Lymphoma Academic Research Organisation
Novartis

Completed

A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma (HIJAK)

Hodgkin's Lymphoma

France, Belgium
The Lymphoma Academic Research Organisation
Lymphoma Study Association

Not yet recruiting

Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

Refractory High Grade B-Cell Lymphoma | Diffuse Large B-cell Lymphoma Refractory | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Refractory Primary Mediastinal Large B-Cell Lymphoma

France
The Lymphoma Academic Research Organisation
Celgene Corporation

Active, not recruiting

A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma (RELEVANCE)

Follicular Lymphoma

Spain, Canada, France, Australia, Italy, Belgium, Germany, Portugal
The Lymphoma Academic Research Organisation
Epizyme, Inc.

Active, not recruiting

Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy (Epi-RCHOP)

Lymphoma | Follicular Lymphoma | DLBCL

France, Belgium
The Lymphoma Academic Research Organisation
Innate Pharma

Recruiting

Study of Lacutamab in Peripheral T-cell Lymphoma

Peripheral T Cell Lymphoma | Relapse/Recurrence

France, Spain, Belgium, Germany
The Lymphoma Academic Research Organisation
Daiichi Sankyo

Active, not recruiting

Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma

Lymphoma, B-Cell

France, Belgium
The Lymphoma Academic Research Organisation
Celgene Corporation

Completed

A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma (CLEAR)

Relapsed/Refractory B-cell Lymphoma

France
The Lymphoma Academic Research Organisation
French Innovative Leukemia Organisation

Completed

Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL). (T³)

Mantle Cell Lymphoma Refractory

France
The Lymphoma Academic Research Organisation
Roche Pharma AG

Recruiting

Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL)

Follicular Lymphoma

France
The Lymphoma Academic Research Organisation
Novartis; Gilead Sciences

Recruiting

French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)

Hematopathology Eligible or CAR-t Cell Treatment

France
The Lymphoma Academic Research Organisation
Karyopharm Therapeutics Inc

Completed

A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP (SELINDA)

B-cell Lymphoma

Belgium, France
The Lymphoma Academic Research Organisation
Centre Henri Becquerel

Completed

Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma (R2-CHOP2)

Follicular Lymphoma

France
The Lymphoma Academic Research Organisation
Millennium Pharmaceuticals, Inc.

Completed

Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE (BV-ICE)

Hodgkin Disease

France, Belgium
The Lymphoma Academic Research Organisation
Roche Pharma AG

Terminated

Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma

France
The Lymphoma Academic Research Organisation
CHU de Nancy

Completed

Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients

DLBCL

France, Belgium
The Lymphoma Academic Research Organisation
Roche Pharma AG

Terminated

Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia (VISMOLY)

Chronic Lymphocytic Leukemia | Primary Central Nervous System Lymphoma | Diffuse Large B-cell Lymphoma | Indolent Non-hodgkin Lymphoma

France
The Lymphoma Academic Research Organisation
Roche Pharma AG

Completed

Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT) (FLIRT)

Follicular Lymphoma

France
The Lymphoma Academic Research Organisation
Millennium Pharmaceuticals, Inc.

Completed

Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma. (BREACH)

Hodgkin Lymphoma

Netherlands, France, Belgium, Croatia, Denmark
The Lymphoma Academic Research Organisation
Centre Henri Becquerel

Completed

Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+

Diffuse Large B Cell Lymphoma

France, Belgium
The Lymphoma Academic Research Organisation
Hoffmann-La Roche

Terminated

GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma (GAINED)

Diffuse Large B Cell Lymphoma CD20 Positive

France, Belgium
Hospices Civils de Lyon
The Lymphoma Academic Research Organisation

Recruiting

REal World Data in LYmphoma and Survival in Adults (REALYSA)

Mantle Cell Lymphoma (MCL) | Follicular Lymphoma (FL) | Diffuse Large B Lymphoma (DLBCL) | Marginal Zone Lymphoma (MZL) | T-cell Lymphoma (T-NHL) | Hodgkin's Lymphoma (HL) | Burkitt Lymphoma (BL))

France

Clinical Trials Sponsored by The Lymphoma Academic Research Organisation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations